Form D · Biotechnology
Anumana, Inc.
Cambridge, MA · CIK 0001953923
Offering snapshot reported Nov 17, 2022 · SEC filing
- Reported sold
- $32M Offering amount: $32M
- Investors reported
- 72 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 4, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 17, 2022 | Initial | $32,000,000 | No comparison | 72 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-465157
Source: Form D, filed Nov 17, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Murali Aravamudan | Director, Executive |
| Kyle Bettigole | Executive |
| Alan Colowick | Director |
| Harris Fishman | Executive |
| David Goel | Director |
| Cheranjit Rihal | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Main Street Suite 400
Cambridge, MA, 02142
Cambridge, MA, 02142